INT145710

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.75
First Reported 2007
Last Reported 2010
Negated 0
Speculated 0
Reported most in Abstract
Documents 9
Total Number 9
Disease Relevance 1.66
Pain Relevance 2.89

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

small molecule metabolic process (CYP2C9) oxidoreductase activity (CYP2C9) endoplasmic reticulum (CYP2C9)
CYP2C9 (Homo sapiens)
Pain Link Frequency Relevance Heat
aspirin 16 99.58 Very High Very High Very High
cINOD 27 99.46 Very High Very High Very High
Duloxetine 33 96.76 Very High Very High Very High
opioid receptor 1 82.48 Quite High
Serotonin 37 80.04 Quite High
Potency 3 77.00 Quite High
noradrenaline 25 75.00 Quite High
COX-2 inhibitor 1 75.00 Quite High
depression 41 62.52 Quite High
Nicotine 3 31.04 Quite Low
Disease Link Frequency Relevance Heat
Toxicity 7 99.56 Very High Very High Very High
INFLAMMATION 11 99.18 Very High Very High Very High
Hemorrhage 8 91.04 High High
Genetic Predisposition To Disease 2 75.00 Quite High
Depression 48 62.52 Quite High
Muscle Disease 1 60.20 Quite High
Reprotox - General 1 1 48.88 Quite Low
Reprotox - General 2 6 48.00 Quite Low
Vomiting 8 44.20 Quite Low
Disease 13 25.20 Quite Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Nonsteroidal anti-inflammatory drugs (NSAIDs), other than aspirin, are to some extent metabolized by cytochrome P450 2C9 (CYP2C9).
Localization (metabolized) of CYP2C9 associated with aspirin, inflammation and cinod
1) Confidence 0.75 Published 2010 Journal Clin. Pharmacol. Ther. Section Abstract Doc Link 20445534 Disease Relevance 0.26 Pain Relevance 0.73
BACKGROUND AND AIMS: Several nonsteroidal anti-inflammatory drugs (NSAIDs) are metabolized by the cytochrome P450 2C9 (CYP2C9).
Localization (metabolized) of CYP2C9 associated with inflammation and cinod
2) Confidence 0.75 Published 2007 Journal Gastroenterology Section Abstract Doc Link 17681167 Disease Relevance 0.32 Pain Relevance 0.36
Here we present frequencies of the most common CYP2C9 coding variants CYP2C9*2 (C430T) and CYP2C9*3 (A1075C) in representative samples of four regions from Spain (Basque Country, n=358; Catalonia, n=240; Central Spain, n=190 and Galicia, n=288) and one northern Italian region, (Verona, n=164), which range between 0.125 and 0.165 in the case of CYP2C9*2 and between 0.071 and 0.085 for CYP2C9*3.
Localization (case) of CYP2C9
3) Confidence 0.75 Published 2009 Journal Pharmacogenomics J. Section Abstract Doc Link 19381164 Disease Relevance 0.09 Pain Relevance 0
Linkage disequilibrium between CYP2C9 and CYP2C8
Localization (disequilibrium) of CYP2C9
4) Confidence 0.72 Published 2009 Journal Pharmacogenomics J Section Body Doc Link PMC2782405 Disease Relevance 0.18 Pain Relevance 0
Nonsteroidal anti-inflammatory drugs (NSAIDs), other than aspirin, are to some extent metabolized by cytochrome P450 2C9 (CYP2C9).
Localization (metabolized) of cytochrome P450 2C9 associated with aspirin, inflammation and cinod
5) Confidence 0.65 Published 2010 Journal Clin. Pharmacol. Ther. Section Abstract Doc Link 20445534 Disease Relevance 0.26 Pain Relevance 0.73
BACKGROUND AND AIMS: Several nonsteroidal anti-inflammatory drugs (NSAIDs) are metabolized by the cytochrome P450 2C9 (CYP2C9).
Localization (metabolized) of cytochrome P450 2C9 associated with inflammation and cinod
6) Confidence 0.65 Published 2007 Journal Gastroenterology Section Abstract Doc Link 17681167 Disease Relevance 0.32 Pain Relevance 0.35
The aim of the present investigation is to use rational design together with MetaSite, a metabolism site prediction program, to synthesize compounds that retain their pharmacological effects but that are metabolically more stable in the presence of CYP2C9.
Localization (presence) of CYP2C9
7) Confidence 0.61 Published 2007 Journal J. Med. Chem. Section Abstract Doc Link 17696334 Disease Relevance 0.10 Pain Relevance 0.13
Extensive metabolism, predominantly via CYP1A2, to a lesser extent via CYP2D6, and at a very low rate via CYP2C9,151,152 has been reported, but the metabolites have no significant activity.153 Duloxetine is a moderate CYP2D6 inhibitor and may inhibit its own metabolism154,155 as well as the metabolism of CYP2D6 substrates, such as desimipramine.90,195 The inhibition or induction of CYP1A2 is not clinically important, and coadministration of duloxetine with CYP1A2 substrates does not necessitate their dose adjustment.193 However, potent inhibitors of CYP2D6 and CYP1A2 may result in enhanced duloxetine concentrations and a need for dose adjustment.191,193
Localization (rate) of CYP2C9 associated with duloxetine
8) Confidence 0.50 Published 2010 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2938284 Disease Relevance 0.06 Pain Relevance 0.58
The statins are a good example, because simvastatin and lovastatin are extensively metabolized by CYP3A4, atorvastatin is moderately metabolized by CYP3A4, fluvastatin is metabolized by CYP2C9, and pravastatin and rosuvastatin are not metabolized by cytochrome P450 isozymes.[18] Thus, combining all members of this drug class together is rarely justified when considering drug interactions.
Localization (metabolized) of CYP2C9
9) Confidence 0.16 Published 2010 Journal Journal of Young Pharmacists : JYP Section Body Doc Link PMC2964764 Disease Relevance 0.06 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox